Form 4: BioXcel Therapeutics CFO Richard Steinhart Reports Stock Transactions
SEC Form 4 Filing
Richard Steinhart, CFO of BioXcel Therapeutics, reports acquisition of shares through vested restricted stock units and subsequent sale of shares under a pre-arranged trading plan.
Summary
- Richard Steinhart, the CFO of BioXcel Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On September 17, 2024, 21,250 shares of common stock became issuable to Steinhart due to the satisfaction of performance conditions related to restricted stock units (PSUs).
- These PSUs were previously granted and would vest based on the company's achievement of certain performance objectives and Steinhart's continued service through October 1, 2024.
- On October 3, 2024, Steinhart sold 7,175 shares of common stock at a weighted average price of $0.55 per share, with individual sales ranging from $0.5500 to $0.5515.
- The sales were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Steinhart directly owns 20,279 shares of BioXcel Therapeutics stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The vesting of PSUs is a positive sign, but the subsequent sale of shares introduces a slightly negative element, although it was pre-planned.
Positives
- The vesting of PSUs indicates that BioXcel Therapeutics met certain performance objectives, which could be viewed positively.
Negatives
- The sale of shares by the CFO, even under a pre-arranged plan, could be interpreted negatively by some investors.
Risks
- Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this sale was conducted under a pre-arranged trading plan.
Industry Context
Executive stock transactions are common and closely monitored by investors for insights into a company's prospects. Rule 10b5-1 plans are often used to mitigate concerns about insider trading.
Stakeholder Impact
- Shareholders may react to the stock sale, although the pre-arranged nature of the sale could mitigate concerns.
Key Dates
| Date | Description |
|---|---|
| December 14, 2023 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| September 17, 2024 | Date of acquisition of 21,250 shares due to PSU vesting |
| October 1, 2024 | Date shares of common stock became issuable to the Reporting Person |
| October 3, 2024 | Date of sale of 7,175 shares at an average price of $0.55 |
Keywords
BioXcel Therapeutics, BTAI, Richard Steinhart, CFO, Form 4, Stock Sale, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.